Drug Profile
XAF 5
Alternative Names: XAF-5; XOPH5Latest Information Update: 19 May 2020
Price :
$50
*
At a glance
- Originator Harvard Medical School
- Developer Allergan
- Class Small molecules
- Mechanism of Action Adipocyte inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Subcutaneous fat disorders
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 26 Jun 2019 Discontinued - Phase-II for Subcutaneous fat disorders in USA (Topical)
- 26 Jun 2019 Discontinued - Phase-II/III for Subcutaneous fat disorders (In the elderly, In adults) in USA (Topical)